Safety of heterologous ChAdOx1-S/BNT162b2 primary schedule versus homologous BNT162b2 vaccination: Insights from an Italian post-marketing study, 2021

During COVID-19 vaccination campaign, possible ChAdOx1-S-associated risks of thrombosis with thrombocytopenia syndrome led to implement ChAdOx1-S/BNT162b2 heterologous vaccination, despite the limited information on its reactogenicity and safety. We conducted a prospective observational post-marketi...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Francesca Fortunato, Rosa Prato, Giuseppina Iannelli, Leonardo Ascatigno, Daniela Loconsole, Pier Luigi Lopalco, Domenico Martinelli
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Taylor & Francis Group 2023-01-01
coleção:	Human Vaccines & Immunotherapeutics
Assuntos:	covid-19 vaccination heterologous primary schedule chadox1-s vaccine bnt162b2 vaccine safety post-marketing surveillance italy
Acesso em linha:	http://dx.doi.org/10.1080/21645515.2023.2209919
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!